Bilobetin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Bilobetin 通过 PKA 介导的 PPARα 磷酸化改善高脂饮食大鼠的胰岛素抵抗。

Bilobetin ameliorates insulin resistance by PKA-mediated phosphorylation of PPARα in rats fed a high-fat diet.

Cell Viability Assay Cell Line:Huh7 and HepG2 cells Concentration:0, 2.5, 5, 10, 20, and 40 μM Incubation Time:24/48/72 h Result:Inhibited cell proliferation in a dose dependent manner, with IC50s of 18.28 μM at 48 h in Huh7 cells, and 19 μM at 72 h in HepG2 cells.Apoptosis Analysis Cell Line:Huh7 and HepG2 cells Concentration:0, 2.5, 5, 10, 20 μM Incubation Time:24/48 h Result:Showed the total apoptotic cell rate of 2.2, 2.2, 1.9, and 10.6% for 24 h (Huh7 cells) at 0, 5, 10, and 20 μM, and 1.7, 1.5, 7.5, and 22.5% for 48 h (Huh7 cells) at 0, 5, 10, and 20 μM.Showed the total apoptotic cell rate of 1.1, 1.2, 1.6, and 3.0% for 24 h (Huh7 cells) at 0, 5, 10, and 20 μM, and 1.5, 1.1, 3.2, and 14.2% for 48 h (Huh7 cells) at 0, 5, 10, and 20 μM, respectively.

Animal Model:rats fed a high-fat dietDosage:12 mg/kg/dayAdministration:i.p., 4 or 14 days after mice were fed a HFD for 8 weeks.Result:Increased glucose infusion rate (GIR, P < 0.05) and reduced EGP (P < 0.05) in basal and clamp states.Reduced total TG (P < 0.01) and VLDL-TG (P < 0.01).Enhances hepatic Intralipid-TG uptake.Reduced the total amount of lipid level in the liver and muscle.Promoted the phosphorylation of PPARα and the translocation of PPARα from the cytoplasm to the nucleus in rats liver.

——

Others

Other Targets

PPARα

Others-Field

——

521-32-4

552.49

C31H20O10

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (452.51 mM)

Oc1cc(O)cc2OC(=CC(=O)c12)c6cc(c5c(O)cc(O)c3c5OC(=CC3=O)c4ccc(O)cc4)c(OC)cc6

——

(-20℃)

With Ice Pack

≥ 2 years